{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:34:19Z","timestamp":1768012459801,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12325-022-02252-9","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:40:23Z","timestamp":1659091223000},"page":"4299-4314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study"],"prefix":"10.1007","volume":"39","clinical-trial-number":[{"clinical-trial-number":"umin000044682","registry":"10.18810\/umin-japan"}],"author":[{"given":"Akitoyo","family":"Hishimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-3770","authenticated-orcid":false,"given":"Norio","family":"Yasui-Furukori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8677-3626","authenticated-orcid":false,"given":"Daisuke","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2632-8808","authenticated-orcid":false,"given":"Miyuki","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7913-4041","authenticated-orcid":false,"given":"Sakiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"issue":"6","key":"2252_CR1","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","volume":"39","author":"E J\u00e4\u00e4skel\u00e4inen","year":"2013","unstructured":"J\u00e4\u00e4skel\u00e4inen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296\u2013306.","journal-title":"Schizophr Bull"},{"issue":"3","key":"2252_CR2","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/npr2.12193","volume":"41","author":"Japanese Society of Neuropsychopharmacology","year":"2021","unstructured":"Japanese Society of Neuropsychopharmacology. Japanese Society of Neuropsychopharmacology: guideline for pharmacological therapy of schizophrenia. Neuropsychopharmacol Rep. 2021;41(3):266\u2013324.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"3","key":"2252_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241\u20137.","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 14","key":"2252_CR4","first-page":"27","volume":"68","author":"JM Kane","year":"2007","unstructured":"Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68(Suppl 14):27\u201330.","journal-title":"J Clin Psychiatry"},{"key":"2252_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1192\/bjp.184.4.346","volume":"184","author":"S Almond","year":"2004","unstructured":"Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184:346\u201351.","journal-title":"Br J Psychiatry"},{"key":"2252_CR6","doi-asserted-by":"crossref","unstructured":"Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1\u201346; quiz 47\u20138.","DOI":"10.4088\/JCP.7090su1cj"},{"key":"2252_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/PPA.S124658","volume":"11","author":"DI Velligan","year":"2017","unstructured":"Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449\u201368.","journal-title":"Patient Prefer Adherence"},{"issue":"10202","key":"2252_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939\u201351.","journal-title":"Lancet"},{"issue":"3","key":"2252_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589\u2013604.","journal-title":"J Pharmacol Exp Ther"},{"key":"2252_CR10","unstructured":"US Food and Drug Administration. REXULTI\u00ae (brexpiprazole) tablets, for oral use. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/205422s007lbl.pdf. Accessed 26 July 2022."},{"key":"2252_CR11","unstructured":"Otsuka Pharmaceutical Co., Ltd. Rexulti tablet 1mg\/ rexulti tablet 2mg. (Brexpiprazole) Prescribing information. 2018. https:\/\/www.info.pmda.go.jp\/go\/pack\/1179058F1020_1_04\/ (in Japanese). Accessed 26 July 2022."},{"issue":"9","key":"2252_CR12","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","volume":"172","author":"CU Correll","year":"2015","unstructured":"Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-Week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870\u201380.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"2252_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/pcn.12682","volume":"72","author":"J Ishigooka","year":"2018","unstructured":"Ishigooka J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2018;72(9):692\u2013700.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1\u20133","key":"2252_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.schres.2016.04.013","volume":"174","author":"JM Kane","year":"2016","unstructured":"Kane JM, Skuban A, Hobart M, et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res. 2016;174(1\u20133):93\u20138.","journal-title":"Schizophr Res"},{"issue":"3","key":"2252_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1124\/jpet.114.213819","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605\u201314.","journal-title":"J Pharmacol Exp Ther"},{"key":"2252_CR16","unstructured":"Pharmacy Quality Alliance. PQA adherence measures [updated 2018\/8\/28]. https:\/\/www.pqaalliance.org\/adherence-measures. Accessed 10 Feb 2022."},{"key":"2252_CR17","unstructured":"University Hospital Medical Information Network Center (UMIN). Clinical Trials Registry (CTR) ID: UMIN000044682. Treatment persistence and medication adherence in patients with schizophrenia treated with brexpiprazole versus other oral atypical antipsychotic therapy\u2014cohort study using claim database. 2021. https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi?function=brows&action=brows&recptno=R000051007&type=summary&language=J (in Japanese). Accessed 10 Feb 2022."},{"issue":"12","key":"2252_CR18","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323.","journal-title":"N Engl J Med"},{"key":"2252_CR19","doi-asserted-by":"publisher","first-page":"5559","DOI":"10.2147\/DDDT.S240859","volume":"14","author":"Y Watanabe","year":"2020","unstructured":"Watanabe Y, Yamada S, Otsubo T, Kikuchi T. Brexpiprazole for the treatment of schizophrenia in adults: An overview of its clinical efficacy and safety and a psychiatrist\u2019s perspective. Drug Des Devel Ther. 2020;14:5559\u201374.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"2252_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/pcn.12275","volume":"69","author":"T Inada","year":"2015","unstructured":"Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69(8):440\u20137.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"11","key":"2252_CR21","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"2","key":"2252_CR22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J Roy Stat Soc Ser B (Methodology). 1972;34(2):187\u2013220.","journal-title":"J Roy Stat Soc Ser B (Methodology)"},{"key":"2252_CR23","unstructured":"Otsuka Pharmaceutical Co., Ltd. Abilify. (Aripiprazole) Prescribing information 2022. https:\/\/www.info.pmda.go.jp\/go\/pack\/1179045B1021_1_35\/ (in Japanese). Accessed 17 Feb 2022."},{"issue":"4","key":"2252_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/JCP.0000000000000523","volume":"36","author":"S Garc\u00eda","year":"2016","unstructured":"Garc\u00eda S, Mart\u00ednez-Cengotitabengoa M, L\u00f3pez-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol. 2016;36(4):355\u201371.","journal-title":"J Clin Psychopharmacol"},{"key":"2252_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-244X-10-2","volume":"10","author":"H Ascher-Svanum","year":"2010","unstructured":"Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2.","journal-title":"BMC Psychiatry"},{"key":"2252_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-244X-8-32","volume":"8","author":"G Morken","year":"2008","unstructured":"Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008;8:32.","journal-title":"BMC Psychiatry"},{"issue":"5","key":"2252_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2109","volume":"11","author":"Y Inoue","year":"2021","unstructured":"Inoue Y, Suzuki H, Hibino H, et al. Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia. Brain Behav. 2021;11(5):e02109.","journal-title":"Brain Behav"},{"issue":"1\u20133","key":"2252_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.schres.2016.04.012","volume":"174","author":"CU Correll","year":"2016","unstructured":"Correll CU, Skuban A, Hobart M, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. Schizophr Res. 2016;174(1\u20133):82\u201392.","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"2252_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","volume":"164","author":"JM Kane","year":"2015","unstructured":"Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1\u20133):127\u201335.","journal-title":"Schizophr Res"},{"issue":"6","key":"2252_CR30","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/pcn.12654","volume":"72","author":"J Ishigooka","year":"2018","unstructured":"Ishigooka J, Iwashita S, Tadori Y. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: a 52-week, open-label study. Psychiatry Clin Neurosci. 2018;72(6):445\u201353.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"2252_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/ijnp\/pyy002","volume":"21","author":"A Forbes","year":"2018","unstructured":"Forbes A, Hobart M, Ouyang J, Shi L, Pfister S, Hakala M. A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia. Int J Neuropsychopharmacol. 2018;21(5):433\u201341.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"2252_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13696998.2017.1379412","volume":"21","author":"M Greene","year":"2018","unstructured":"Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018;21(2):127\u201334.","journal-title":"J Med Econ"},{"key":"2252_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jpsychires.2020.05.012","volume":"127","author":"T Hata","year":"2020","unstructured":"Hata T, Kanazawa T, Hamada T, et al. The 12-year trend report of antipsychotic usage in a nationwide claims database derived from four million people in Japan. J Psychiatr Res. 2020;127:28\u201334.","journal-title":"J Psychiatr Res"},{"key":"2252_CR34","unstructured":"Japanese Society for Pharmacoepidemiology. Database available for pharmacoepidemiology researches in Japan: information obtained from survey answers as of August 2019. 2019. https:\/\/drive.google.com\/file\/d\/1wlX96kYd-rPT_OgBRjjt-Yq1XHeL0qLN\/view. Accessed 7 Feb 2022."},{"key":"2252_CR35","unstructured":"Statistics of Japan. Population estimates: population by age (5-year age group) and sex, monthly estimates\u2014Total population, Japanese population, the first day, each month 2020. https:\/\/www.e-stat.go.jp\/ (in Japanese). Accessed 8 Mar 2022."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02252-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02252-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02252-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T05:14:54Z","timestamp":1727673294000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02252-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2252"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02252-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"18 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}